Compare Charles Schwab Corporation Common Stock (SCHW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs TG Therapeutics Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $96.93 (market cap $167.52B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 20.5× TG Therapeutics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and TG Therapeutics Inc for 16 Days on average.
| SCHW | TGTX | |
|---|---|---|
Market Cap | $167.52B | $8.16B |
Volume | 6,554,126 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $113.65 | $59.06 |
52-Week Low | $85.35 | $26.94 |
Typical Hold Time | 85 Days | 16 Days |
Enterprise Value | $153.97B | $8.37B |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.70, up 1.17% with bearish technical signals but strong fundamentals. The company reported record quarterly revenue of $7.08 billion (The Motley Fool, 2026-09-29) and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.33 price target, representing 24% upside potential. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships with Anthropic.
SCHW offers compelling value with a P/E of 17.64 and robust 38.79% net margin, though technical indicators signal near-term caution. The stock faces risks from narrowing interest spreads and market volatility, but strong earnings momentum and institutional support provide solid foundation for long-term growth.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
